Genmab A/S (NASDAQ:GMAB) Given Average Recommendation of "Moderate Buy" by Brokerages

Genmab A/S (NASDAQ:GMAB - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $45.20.

GMAB has been the topic of several recent analyst reports. Morgan Stanley reissued an "equal weight" rating and set a $31.00 target price on shares of Genmab A/S in a report on Wednesday, September 11th. Truist Financial dropped their price objective on Genmab A/S from $53.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, September 9th. Redburn Atlantic assumed coverage on Genmab A/S in a research note on Tuesday, October 8th. They set a "buy" rating for the company. BMO Capital Markets reiterated an "outperform" rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a report on Wednesday, October 16th.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB traded up $0.22 on Friday, hitting $20.31. The company's stock had a trading volume of 1,829,681 shares, compared to its average volume of 751,032. The company has a market capitalization of $13.44 billion, a price-to-earnings ratio of 19.72, a price-to-earnings-growth ratio of 0.67 and a beta of 0.96. Genmab A/S has a 12 month low of $19.85 and a 12 month high of $32.88. The stock's 50-day moving average is $21.87 and its two-hundred day moving average is $24.87.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). The company had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period in the previous year, the business posted $0.47 EPS. Equities analysts expect that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC lifted its position in shares of Genmab A/S by 123.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 3,240 shares of the company's stock valued at $81,000 after acquiring an additional 1,787 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Genmab A/S by 892.0% in the third quarter. Blue Trust Inc. now owns 4,315 shares of the company's stock valued at $108,000 after purchasing an additional 3,880 shares in the last quarter. Headlands Technologies LLC lifted its holdings in shares of Genmab A/S by 1,702.8% in the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company's stock valued at $129,000 after purchasing an additional 4,853 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in shares of Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company's stock worth $182,000 after buying an additional 478 shares during the period. Finally, Mount Yale Investment Advisors LLC purchased a new position in shares of Genmab A/S during the third quarter valued at $192,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.